In 1591 Italian subjects affected by SARS-COV-2, there was a prevalence of 17% of type 2 diabetes [1]. In analogy to what has been shown in a Chinese population [2] and in another group of Italian subjects [3], surprisingly no cases with type 1 diabetes are apparently reported. This observation needs to be confirmed and further evaluated, for example in regions with high prevalence of the disease (Scandinavian, Finland or Sardinian), but there could be a number of reasons that justify a low incidence of SARS-COV-2 in subjects with type 1 diabetes. This result may be apparently linked to the younger age of type 1 diabetes subjects and the lower prevalence of the disease, if compared to type 2 diabetes in general population, but it could have some intriguing implications. Type 1 diabetes subjects, initially classified as a high-risk category in some countries as Italy, might have taken advantage of an early application of social distancing measures, such as smart working, indirectly supporting this kind of approach to reduce the prevalence and the negative outcomes of the infection. At the same time, from a pathophysiologycal point of view, type 1 diabetes is an autoimmune disorder characterized by a dysregulation of adaptative immunity with an overexpression of CD8+ T lymphocytes [4]. It is conceivable that this immunological attitude might play a protective role during SARS-COV2 infection, in which CD8+ T lymphocytes show an increased apoptosis resulting in lymphocytopenia. Indeed, we cannot rule out that there are some asymptomatic subjects with SARS-COV-2 infection in type 1 diabetic population. Finally, while the infected population has a high prevalence of hypertension, type 1 diabetes is often characterized by hyperglycemia in the absence of the other cardiovascular risk factors. It could mean and suggest that the metabolic disturbance per se is unrelated to the outcomes of this viral infection.
Author contribution
All the authors have made substantive contributions to the article and assume full responsibility for its content.
Funding
The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- 1.Grasselli Giacomo, Zangrillo Alberto, Zanella Alberto, Antonelli Massimo, Cabrini Luca, Castelli Antonio, Cereda Danilo, Coluccello Antonio, Foti Giuseppe, Fumagalli Roberto, Iotti Giorgio, Latronico Nicola, Lorini Luca, Merler Stefano, Natalini Giuseppe, Piatti Alessandra, Ranieri Marco Vito, Scandroglio Anna Mara, Storti Enrico, Cecconi Maurizio, Pesenti Antonio. Baseline characteristics and outcomes of 1591 patients infected With SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574. doi: 10.1001/jama.2020.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wu Z., McGoogan Characteristic of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
- 3.Fadini G.P., Morieri M.L., Longato E., Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867–869. doi: 10.1007/s40618-020-01236-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Pitocco D., Di Leo M., Tartaglione L., De Leva F., Petruzziello C., Saviano A. The role of gut microbiota in mediating obesity and diabetes mellitus. Eur Rev Med Pharmacol Sci. 2020;24(3):1548–1562. doi: 10.26355/eurrev_202002_20213. [DOI] [PubMed] [Google Scholar]